Please use this identifier to cite or link to this item: http://hdl.handle.net/1959.13/928952

OpenURL Link
Title
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Author/Creator
Tebbutt, Niall C.;  Wilson, Kate;  Forgeson, Garry;  Cunningham, David;  Saunders, Mark P.;  Stockler, Martin R.;  Chua, Yujo;  Zalcberg, John R.;  Simes, R. John;  Price, Timothy J.;  Gebski, Val J.;  Cummins, Michelle M.;  Zannino, Dianna;  van Hazel, Guy A.;  Robinson, Bridget;  Broad, Adam;  Ganju, Vinod;  Ackland, Stephen P.
Institution
The University of Newcastle. Faculty of Health, School of Health Science
Description
Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial. Patients and Methods: Overall, 471 patients in Australia, New Zealand, and the United Kingdom with previously untreated, unresectable mCRC were randomly assigned to the following: capecitabine; capecitabine plus bevacizumab (CB); or capecitabine, bevacizumab, and mitomycin (CBM). We compared CB with capecitabine and CBM with capecitabine for progression-free survival (PFS). Secondary end points included overall survival (OS), toxicity, response rate (RR), and quality of life (QOL). Results: Median PFS was 5.7 months for capecitabine, 8.5 months for CB, and 8.4 months for CBM (capecitabine v CB: hazard ratio [HR], 0.63; 95% CI, 0.50 to 0.79; P < .001; C v CBM: HR, 0.59; 95% CI, 0.47 to 0.75; P < .001). After a median follow-up of 31 months, median OS was 18.9 months for capecitabine and was 16.4 months for CBM; these data were not significantly different. Toxicity rates were acceptable, and all treatment regimens well tolerated. Bevacizumab toxicities were similar to those in previous studies. Measures of overall QOL were similar in all groups. Conclusion: Adding bevacizumab to capecitabine, with or without mitomycin, significantly improves PFS without major additional toxicity or impairment of QOL.
Relation
Journal of Clinical Oncology Vol. 28, Issue 19, p. 3191-3198
Publisher Link
http://dx.doi.org/10.1200/jco.2009.27.7723
Date
2010
Publisher
American Society of Clinical Oncology
Keyword(s)
metastatic colorectal cancer;  bevacizumab;  capecitabine monotherapy;  mitomycin
Resource Type
journal article
Identifier
http://hdl.handle.net/1959.13/928952
Identifier
ISSN:0732-183X
Reviewed
Reviewed
21 Visitors 23 Hits 0 Downloads
Save/E-mail Citation
Citation Format
E-mail Address
Subject
"Journal of Clinical Oncology"
 
OR